ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Humacyte, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Humacyte securities is from May 10, 2024, to October 17, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 17, 2025 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked highly in securities class action settlements, recovering hundreds of millions of dollars for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Humacyte made false or misleading statements regarding its manufacturing practices and the FDA approval process for its Acellular Tissue Engineered Vessel (ATEV) [4]. - Specific claims include non-compliance with good manufacturing practices at Humacyte's facility and delays in the FDA's review of the Biologics License Application due to remediation needs [4]. - The lawsuit asserts that these misrepresentations led to investor damages when the true information became public [4].